Table 3.
Estimated Kaplan-Meier median survival time (MST), rate of survival at 2 years, and Cox regression analyses for 35 patients with advanced intrahepatic cholangiocarcinoma.
| Test | AV | Number of Patients | MST | 2-yr S | HR | CI | P |
|---|---|---|---|---|---|---|---|
| – | – | # (%) | Months | % | – | – | – |
| NLR | < 3 | 15 (43) | >24 | 92 | 0.15 | 1.7–25.2 | 6.4x10-3 |
| ≥ 3 | 20 (57) | 17 | 34 | 6.54 | |||
| ANC | ≤ 8 | 25 (71) | >24 | 84 | 0.20 | 1.6–15.7 | 6.5x10-3 |
| > 8 | 10 (29) | 17 | 18 | 4.95 | |||
| WBC | < 10 | 24 (69) | >24 | 84 | 0.22 | 1.4–14.4 | 0.01 |
| ≥ 10 | 11 (31) | 17 | 19 | 4.53 | |||
| Platelets | ≤ 300 | 25 (71) | >24 | 84 | 0.20 | 1.3–17.8 | 0.02 |
| > 300 | 10 (29) | 17 | 27 | 4.88 | |||
| Albumin | ≥ 3.5 | 26 (74) | >24 | 72 | 0.24 | 1.2–14.4 | 0.03 |
| < 3.5 | 9 (26) | 17 | 36 | 4.1 | |||
| Lymph | ≥ 1.5 | 21 (60) | >24 | 68 | 0.50 | 0.6–6.56 | 0.27 |
| < 1.5 | 14 (40) | >24 | 57 | 1.98 | |||
| AlP | < 135 | 13 (37) | >24 | 92 | 0.63 | 0.5–4.79 | 0.42 |
| ≥ 135 | 22 (63) | 22.1 | 49 | 1.58 | |||
| LMR | ≥ 2.1 | 25 (71) | >24 | 74 | 0.68 | 0.5–4.18 | 0.50 |
| < 2.1 | 10 (29) | 22.1 | 47 | 1.6 |
Statistical tests compare stratification for individual assay values (AV) with validated prognostic blood tests (PBTs). These include neutrophil lymphocyte ratio (NLR), absolute neutrophil count (ANC), white blood count (WBC), platelets, serum albumin, lymphocytes (lymph), alkaline phosphatase (AlP), and lymphocyte monocyte ratio (LMR). Statistical tests compare stratification for each individual AV as a low vs. high-risk test group, measuring the hazard ratio (HR), 95% confidence interval (CI), and P value. Survival is measured from the first day of treatment with GFLIO. At the time of subsequent progression, the first drugs added were docetaxel and mitomycin, followed by the added target drugs, cetuximab and bevacizumab.